GlassScriptPhysician profile
Jorge Carlos Busse
NPI 1922091248
$28,317.42
in general payments reported to CMS, 2019-2025
26 companies · $2,364 in 2025
The $2,364 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,974 · 2020: $6,851 · 2021: $5,566 · 2022: $668 · 2023: $448 · 2024: $2,446 · 2025: $2,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,234 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,233.84 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $12,846.48 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $9,840.51 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $792.89 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $655.63 | 2021-2025 | |
| Travere Therapeutics, INC. | $596.55 | 2023-2025 | |
| Amgen INC. | $533.71 | 2019-2025 | Repatha, Repatha, Tavneos |
| Aurinia Pharma U.S., INC. | $475.92 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $437.45 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $401.75 | 2022-2025 | Acthar, Terlivaz |
| Ardelyx, INC. | $379.42 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.30 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $164.45 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $144.23 | 2021-2023 | Jesduvroq |
| Genzyme Corporation | $124.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $94.90 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $84.88 | 2025 | |
| Kyowa Kirin, INC. | $69.70 | 2023-2025 | Crysvita |
| Akebia Therapeutics INC | $68.57 | 2024 | Vafseo, Auryxia |
| Lilly USA, LLC | $63.81 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $59.14 | 2023 | Ellipsys Vascular Access System |
| Alnylam Pharmaceuticals INC. | $56.95 | 2024-2025 | Oxlumo |
| Fresenius USA Marketing, INC. | $50.09 | 2021-2024 | Velphoro |
| Cycle Pharmaceuticals INC | $50.00 | 2024-2025 | Venxxiva, Tiopronin |
| Opko Pharmaceuticals, LLC | $42.89 | 2019-2024 | Rayaldee |
| Cormedix INC. | $38.94 | 2024-2025 | Defencath, Defencath |
| Horizon Therapeutics Plc | $26.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Busse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.